KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting

Blood. 2017 Dec 28;130(26):2900-2902. doi: 10.1182/blood-2017-06-792382. Epub 2017 Oct 31.

Authors

Maxime Battistella^{1

2}, Christophe Leboeuf², Caroline Ram-Wolff^{3

4}, Charlotte Hurabielle^{3

4}, Cécile Bonnafous⁵, Hélène Sicard⁵, Armand Bensussan⁴, Martine Bagot^{3

4}, Anne Janin^{1

2}

Affiliations

¹ Pathology Department, Assistance Publique Hôpitaux de Paris Hôpital Saint Louis, Paris, France.
² INSERM U1165, Université Paris 7, Paris, France.
³ Dermatology Department, Assistance Publique Hôpitaux de Paris Hôpital Saint Louis, Paris, France.
⁴ INSERM U976, Université Paris 7, Paris, France; and.
⁵ Innate Pharma, Marseille-Luminy, France.

PMID: 29089310
DOI: 10.1182/blood-2017-06-792382

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Female
Humans
Lymphoma, T-Cell, Cutaneous / diagnosis
Lymphoma, T-Cell, Cutaneous / metabolism*
Lymphoma, T-Cell, Cutaneous / mortality
Male
Middle Aged
Prognosis
Receptors, KIR3DL2 / analysis*
Receptors, KIR3DL2 / metabolism
Risk Factors
Sezary Syndrome
Skin Neoplasms
Survival Analysis

Substances

Receptors, KIR3DL2